21 research outputs found

    1.avi

    No full text
    An easy fabricated, simple control and label-free micro-detection system was demonstrated in a PDMS chip and a new method to distinguish particle’ size in a FBG-FP cavity is exhibited. In our experiment, The period of FBG is 535.5 nm and the left and right length of the FBG is 5 mm and 3 mm, respectively. An amplified spontaneous emission (ASE) source with wavelength from 1528 nm to 1573 nm is coupled into the input fiber. The output signal is detected by an optical spectral analyzer (OSA, MS9740A) with a resolution of 0.03 nm. Two 25-μm particles pass through the cavity continuously and the flow rate is about 5 μL hr-1. The high-speed OSA clearly shows a rapid spectral change when a particle passes through the cavity

    Plasma TRAIL levels in septic patients and healthy controls.

    No full text
    <p>*compared with healthy controls, P<0.01; # compared with the sepsis group, P<0.05. H: healthy control; S: sepsis; SS: severe sepsis; SH: septic shock.</p

    Clinical characteristics and biochemical data of septic patients.

    No full text
    <p>*<i>P</i><0.05;<sup></sup></p><p>**<i>P</i><0.01. ICU days were compared using Mann-Whitney test. APECHEII score, Ventilation days, HLA-DR and s-TRAIL were compared using one-way ANOVA.</p

    High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma

    No full text
    <div><p>Stearoyl-CoA desaturase 1 (SCD1), the rate-limiting enzymes in the biosynthesis of monounsaturated fatty acids from saturated fatty acids, have been gradually recognized as a potential therapeutic target for various malignancies, particularly in clear-cell renal cell carcinoma (ccRCC). However, the prognostic value of SCD1 in ccRCC is still unknown. The aim of this study is to evaluate the clinical significance of SCD1 expression in patients with ccRCC. SCD1 expression in tumor tissues obtained from 359 patients who underwent nephrectomy for ccRCC are retrospectively assessed. During a median follow-up of 63 months (range: 1–144month), 56 patients in total died before the last follow-up in this study. Survival curves were plotted with the Kaplan–Meier method and compared with the log-rank test. Meanwhile, univariate and multivariate Cox regression models were applied to evaluate the prognostic value of SCD1 expression in overall survival (OS) for ccRCC patients. Moreover, SCD1 was enrolled into a newly built nomogram with factors selected by multivariate analysis, and the calibration was built to evaluate the predictive accuracy of nomogram. High SCD1 expression occurred in 61.6% (221/359) of ccRCC patients, which was significantly associated with age (p = 0.030), TNM stage (p = 0.021), pN stage (p = 0.014), Fuhrman grade (p = 0.014) and tumor sizes (p = 0.040). In multivariate analysis, SCD1 expression was confirmed as an adverse independent prognostic factor for OS. The prognostic accuracy of TNM stage, Fuhrman grade and tumor sizes was significantly increased when SCD1 expression was added. The independent prognostic factors, pT stage, pN stage, Fuhrman grade and tumor sizes, as well as SCD1 expression were integrated to establish a predictive nomogram with high predictive accuracy. Calibration curves revealed optimal consistency between observations and prognosis. In conclusion, high SCD1 expression is an independent prognostic factor for OS in patients with ccRCC. Our data suggest that the expression of SCD1 might guide the clinical decisions for patients with ccRCC.</p></div
    corecore